Vaxart Inc. Stock
Vaxart Inc. Stock
With 0 Sell predictions and 1 Buy predictions the community sentiment towards the Vaxart Inc. stock is not clear.
Our community identified positive and negative aspects for Vaxart Inc. stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Vaxart Inc. stock. On the other hand our users think that "General Risks" could be a problem in the future.
Pros and Cons of Vaxart Inc. in the next few years
Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
S********** s********
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Vaxart Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Vaxart Inc. | - | - | - | - | - | - | - |
| Northwest Biotherapeutics Inc. | 0.000% | -12.162% | -23.529% | -38.679% | -36.893% | -73.251% | -87.850% |
| Larimar Therapeutics Inc. | -1.140% | 4.819% | 21.678% | 9.434% | 4.819% | -4.396% | -60.899% |
| Achieve Life Sciences Inc. | 2.700% | 7.547% | 0.885% | 157.336% | 54.054% | 15.854% | -7.317% |
Comments
Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) had its "outperform" rating re-affirmed by analysts at William Blair.
Show more
Ratings data for AVIR provided by MarketBeat
News
Vaxart Investors Reject Say-on-Pay as CEO Rules Out Reverse Split for Now
Key Points
- Interested in Vaxart, Inc.? Here are five stocks we like better.
- Vaxart shareholders rejected the company’s say-on-pay proposal at its 2026 annual meeting, even as they re-elected
3 Stocks Under $5 With Strong Analyst Upside Potential
At a time when many investors are rotating out of speculative penny stocks, others continue to embrace the risk-reward dynamic. Stocks that trade for under $5 carry a certain amount of risk. Many